NCT06084156View on ClinicalTrials.gov

A Study to Evaluate the DDI of HSK7653 With Metformin

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 10, 2019

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HSK7653

Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg

DRUG

Metformin

Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06084156 - A Study to Evaluate the DDI of HSK7653 With Metformin | Biotech Hunter | Biotech Hunter